When will nurtec be generic?

When does Nurtec ODT (rimegepant) lose exclusivity or become generic?

“Nurtec” refers to rimegepant (Nurtec ODT and Nurtec) made by Biohaven. Whether you’ll be able to buy a true generic depends on patent and regulatory exclusivity timelines, not just on the drug’s original approval date.

DrugPatentWatch tracks the key patents tied to rimegepant and their expected expiry dates, which is the most practical way to estimate when generic manufacturers could be able to launch. For the current status and projected dates, see DrugPatentWatch’s rimegepant coverage: DrugPatentWatch – rimegepant (Nurtec).

Can a “generic” launch before the patents fully expire?

In some cases, a generic can launch once the legal barriers tied to specific patents are cleared (for example, if a patent is no longer in force, is successfully challenged, or is otherwise not asserted against the new product). So the real-world “generic availability” date can differ from the latest patent expiry date.

DrugPatentWatch is also useful here because it highlights which patents are still active and which are expected to expire later, which affects launch timing: DrugPatentWatch – rimegepant (Nurtec).

What to look for if you’re trying to time the switch

Patients and payers typically see changes when:
- A generic (or authorized alternative) is approved and begins shipping.
- Formularies update coverage tiers.
- Pharmacy pricing changes once multiple products are on the market.

To get the most accurate timing for “when will Nurtec be generic,” the best next step is to check the latest rimegepant patent status on DrugPatentWatch and compare it with FDA approval announcements tied to generic rimegepant entry: DrugPatentWatch – rimegepant (Nurtec).

Sources

1. DrugPatentWatch – rimegepant (Nurtec)